View Report
April 26, 2024
Measured Result 5.43 mg / 4.95 mg 108.6% / 99% of label claim
Batch #BTHD24
Dragon Pharma
Dragon Pharma
Latest Laboratory Result TB-500: 5.43 mg · BPC-157: 4.95 mg April 26, 2024 · 108.6% / 99% of label claim View
You will save $32.00
TB 500/BPC 157
Product Information Compound Details
Active Formula TB-500 / BPC-157 Peptide Blend
10 mg/vialTB-500 5 mg
BPC-157 5 mg
Total Strength 10 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Formula Dual-Peptide Blend
Drug Class Research Peptide
Manufacturer Dragon Pharma
$48.00
$80.00
Shipping :
International
U.S. Domestic
Product Overview
TB 500/BPC 157 by Dragon Pharma
TB 500/BPC 157 is a lyophilized powder research peptide blend manufactured by Dragon Pharma, containing 5 mg of TB-500 (Thymosin Beta-4 fragment) and 5 mg of BPC-157 per 2 mL vial for a total strength of 10 mg/vial.
Dual-Peptide Blend Injectable
TB 500/BPC 157 combines two of the most extensively researched synthetic peptides in regenerative medicine contexts. TB-500 is a fragment of the naturally occurring protein thymosin beta-4 that binds actin monomers, regulating cytoskeletal dynamics and promoting cell migration to sites of injury. BPC-157 is a synthetic pentadecapeptide derived from human gastric juice that has been studied primarily in animal models for its effects on angiogenesis, collagen synthesis, and gastrointestinal protection.
The rationale for combining these peptides is mechanistic: TB-500 is investigated for its actin-binding and cell migration properties, while BPC-157 is studied for angiogenesis and tissue repair pathways. This combination, sometimes referenced in community contexts as the "Wolverine Stack," is based on the hypothesis that these complementary mechanisms could produce additive effects on tissue repair. That hypothesis has not been evaluated in any controlled human study.
Neither component is FDA-approved for any human use in the United States. BPC-157 is classified as a Category 2 bulk drug substance under FDA's framework for compounding under Section 503A, meaning it may present significant safety risks when used in compounding and is prohibited in compounded medications pending further evaluation. TB-500 has been evaluated by the FDA for inclusion on the 503A Bulks List, with the agency concluding that available evidence weighs against inclusion due to insufficient safety and effectiveness data.
Key Benefits of TB 500/BPC 157
- Combines two distinct regenerative peptides in a single vial
- TB-500 component studied for actin binding and cell migration
- BPC-157 component studied for angiogenesis and collagen synthesis
- Lyophilized powder form for reconstitution flexibility
- Published laboratory verification available
Form
Lyophilized Powder
TB 500/BPC 157 is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. This form requires reconstitution with a suitable solvent such as bacteriostatic water before use.
Product Profile
TB 500/BPC 157 Profile
TB 500/BPC 157 is a dual-peptide blend that combines a thymosin beta-4 fragment with a gastric-derived pentadecapeptide, each studied through distinct regenerative research pathways.
Dual-Peptide Regenerative Formulation
TB-500 corresponds to the actin-binding region (LKKTETQ) of thymosin beta-4, a naturally occurring protein found in high concentrations in platelets and wound fluids. Its primary mechanism involves sequestration of actin monomers, regulating cytoskeletal dynamics that support cell migration and tissue remodeling. BPC-157 is a synthetic pentadecapeptide that has been studied in animal models for promoting angiogenesis, collagen synthesis, and modulating inflammatory pathways, with research examining effects on skin, gut, and musculoskeletal tissue.
The FDA evaluated TB-500-related bulk drug substances for inclusion on the 503A Bulks List and concluded that the evaluation criteria weigh against inclusion. The agency cited issues including inconsistent naming conventions, multiple salts and derivatives sold under the same common name, and a lack of clinical and nonclinical safety information. BPC-157 is currently a Category 2 bulk drug substance, and the FDA’s Pharmacy Compounding Advisory Committee voted in July 2026 to recommend BPC-157 for inclusion on the 503A Bulks List despite FDA staff recommending against inclusion.
A 2025 systematic review of BPC-157 in orthopedic and sports medicine applications found that of 36 included studies, 35 were preclinical and only one was a human study — an uncontrolled 12-patient retrospective case series of intra-articular injection for chronic knee pain. No human randomized controlled trial data exists for TB-500 in musculoskeletal indications.
Research Status
Preclinical Evidence, No Human RCTs for Either Component
Both peptides lack controlled human trial data for musculoskeletal or performance applications. BPC-157 carries a Category 2 FDA designation reflecting safety concerns including immunogenicity and impurities. TB-500 has no human exposure data identified by FDA. WADA prohibits BPC-157 under S0 (Non-Approved Substances).
TB 500/BPC 157 vs Other Dragon Pharma Preparations
Dragon Pharma offers individual peptide products as alternatives to this combined formulation. BPC 157 is available as a standalone product, as is TB 500. For a three-component regenerative blend that adds GHK-Cu, Glow 60 mg is an alternative option. GHK-CU is available separately for extracellular matrix support.
Laboratory Testing
TB 500/BPC 157 Lab Reports
Published laboratory reports for TB 500/BPC 157 are shown below with the test date, measured concentrations, and percentage of the product's label claims.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
Dosage & Usage
TB 500/BPC 157 Dosage & Usage
The information below is provided for educational reference only. TB-500 and BPC-157 are not FDA-approved for any human use in the United States. All use in non-medical contexts falls outside approved indications.
Typical Dosage Ranges
Because TB 500/BPC 157 is a combined formulation with a fixed 1:1 ratio, dose calculations must account for the proportion of each peptide within the blend. Published research on BPC-157 in animal models most often references doses in the microgram range, while community protocols for TB-500 reference milligram-level doses.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Research/Community (non-medical) | Varies by protocol and component | Protocol-dependent |
| BPC-157 component reference | 200–500 mcg per administration | Subcutaneous, daily or every other day |
| TB-500 component reference | 2–5 mg per week | Split into 2 injections weekly |
| Combined blend (community reference) | 500 mcg–1 mg total per administration | 1–2 times daily |
Common reference ranges for this specific combination are not well characterized in publicly available bodybuilding resources. The table above reflects individual component research rather than validated combination protocols.
Stacking & Cycle Considerations
TB 500/BPC 157 is itself a pre-combined stack and is not typically referenced as a base for additional peptide stacking. In community contexts, the combination is sometimes referenced as a recovery-focused protocol, with cycles typically spanning 4–6 weeks.
Community protocols for peptide blends typically reference breaks between cycles, though this practice is based on community experience rather than validated clinical protocols. Bacteriostatic Water is commonly referenced for reconstitution.
Managing Side Effects
Because TB 500/BPC 157 contains two distinct peptides, the side effect profile is less predictable than for single-compound products. BPC-157 carries a Category 2 designation reflecting FDA-identified risks including immunogenicity, peptide-related impurities, and insufficient safety evidence. TB-500 has no human exposure data identified by FDA, and the agency has cited a lack of clinical and nonclinical safety information.
Injection-site reactions are commonly referenced for both peptides. Systemic reactions to any component would be difficult to attribute to a specific peptide within the blend.
Post-Cycle Therapy (PCT)
TB 500/BPC 157 contains peptides that act on tissue repair pathways rather than the hypothalamic-pituitary-gonadal axis. Post-cycle therapy is therefore not applicable in the context of testosterone suppression, as these peptides do not affect endogenous testosterone production.
Important
Individual Response Varies
Dosing strategies for this combination are not established. The information above is for educational reference and does not constitute medical advice.
Safety & Information
TB 500/BPC 157 Safety Information
Neither TB-500 nor BPC-157 is FDA-approved for any human use in the United States. BPC-157 is a Category 2 bulk drug substance, and TB-500-related substances have been evaluated by FDA with the agency concluding that available evidence weighs against inclusion on the 503A Bulks List.
Important Safety Information
BPC-157’s Category 2 designation reflects FDA-identified risks including immunogenicity, peptide-related impurities, and insufficient safety evidence for suggested administration routes. The FDA’s evaluation of TB-500 noted issues including inconsistent naming conventions, multiple salts and derivatives sold under the same common name, and a lack of clinical and nonclinical safety information.
A 2026 systematic review of BPC-157 in musculoskeletal applications found that 35 of 36 included studies were preclinical, with only one uncontrolled human case series involving 12 patients. No controlled human trial data exists for TB-500 in musculoskeletal indications.
Important
Non-Medical Use
This product is not FDA-approved for human use. Any use outside of research applications falls outside approved indications. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
Potential Adverse Effects
Because TB 500/BPC 157 contains two distinct peptides, the combined safety profile is essentially unknown. No human clinical trials have evaluated the BPC-157 plus TB-500 combination for any indication. Combining under-studied peptides compounds the uncertainty rather than reducing it.
BPC-157’s FDA-identified risks include immunogenicity and peptide-related impurities. TB-500’s human safety data is extremely limited, with the FDA noting a lack of clinical and nonclinical safety information. Injection-site reactions are commonly referenced for each component individually.
Conditions Requiring Medical Evaluation
Individuals with active infections, immunocompromised states, or known hypersensitivity to any peptide component should avoid this product. Because BPC-157 has potential for enhanced immunogenicity, individuals with autoimmune conditions should exercise particular caution.
WADA prohibits BPC-157 under S0 (Non-Approved Substances). TB-500 is also prohibited for competing athletes. The long-term effects of chronic use of any of these peptides have not been established.
Monitoring During Use
In research settings where individual peptides have been studied, monitoring has focused on condition-specific endpoints rather than standardized protocols. In non-medical contexts, individuals commonly reference periodic bloodwork, though the appropriate markers for this combination are not established.
A published laboratory report dated April 26, 2024 measured TB 500/BPC 157 at 5.43 mg TB-500 and 4.95 mg BPC-157. That testing applies to the tested sample only and is separate from any clinical monitoring of the individual.
Product Care
Storage & Handling
Lyophilized peptide blends should be stored tightly sealed in the original container, protected from light, and kept at -20°C for long-term storage. Allow the vial to equilibrate to room temperature before opening to prevent moisture uptake. After reconstitution, store refrigerated at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles.
Keep all peptides and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Shipping & Authenticity
Shipping & Product Authenticity
TB 500/BPC 157 by Dragon Pharma is supplied through the official distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your TB 500/BPC 157 product, use the security code on the vial label and cross-check it on the Dragon Pharma official site. Official presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Storage
TB 500/BPC 157 Storage
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Recommended Conditions
Store the lyophilized (dry) powder tightly sealed in its original container, protected from light, and desiccated at -20°C for long-term storage. Brief handling at refrigerated or ambient conditions is acceptable provided the container is allowed to equilibrate to room temperature before opening to prevent moisture uptake.
Peptide blends are hygroscopic and susceptible to oxidation, so they must be kept dry and away from air and light to limit degradation. After reconstitution, store refrigerated at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles.
Keep out of reach of children. Follow proper handling and sterile technique when administering the product.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C
- Do keep in original packaging, protected from light
- Do refrigerate reconstituted solution (2–8°C)
- Don't expose to moisture or humidity
- Don't freeze reconstituted solution repeatedly
- Don't use if solution looks cloudy or contains particles
Frequently Asked Questions
TB 500/BPC 157 FAQ
Answers to common questions about TB 500/BPC 157, its components, product strength, and regulatory status.
What is TB 500/BPC 157 used for?
TB 500/BPC 157 is a research peptide blend containing TB-500 (a thymosin beta-4 fragment) and BPC-157. In research contexts, these peptides have been studied individually for mechanisms related to tissue repair, angiogenesis, and cell migration. No human clinical trials have evaluated this specific combination for any indication, and all use outside research applications falls outside approved indications.
How often should TB 500/BPC 157 be injected?
Dosing schedules for this specific combination are not well characterized. Individual component research references vary: BPC-157 in the 200–500 mcg range and TB-500 at 2–5 mg per week in community protocols. Any combined protocol would require calculations based on the blend ratio, and such protocols are not validated in human studies.
Does TB 500/BPC 157 require PCT?
No. TB 500/BPC 157 contains peptides that act on tissue repair pathways rather than the hypothalamic-pituitary-gonadal axis. These peptides do not suppress endogenous testosterone production, so post-cycle therapy in the context of testosterone recovery is not applicable.
What do TB-500 and BPC-157 do?
TB-500 is a fragment of thymosin beta-4 that binds actin and has been investigated for cell migration and tissue remodeling. BPC-157 is a synthetic pentadecapeptide studied primarily in animal models for angiogenesis and collagen synthesis. Each has distinct mechanisms, but human clinical evidence for musculoskeletal or performance applications is minimal for both.
How long does TB 500/BPC 157 take to work?
The time course for this combination is not established. Published animal research on individual components describes effects building over a course of administration rather than a single dose producing an instant change. No human data exists to characterize onset of action for either peptide in musculoskeletal applications.
Is the Wolverine Stack the best regenerative peptide approach?
There is no evidence-based “best” approach for regenerative peptides. The combination of BPC-157 and TB-500 is based on mechanistic hypotheses rather than demonstrated clinical outcomes. A 2026 systematic review found that 35 of 36 included BPC-157 studies were preclinical, and no human randomized controlled trial data exists for TB-500 in musculoskeletal indications.
What is the difference between TB 500/BPC 157 and individual BPC-157 or TB-500 products?
What is the difference between TB 500/BPC 157 and Glow 60 mg?
Glow 60 mg is a three-component blend containing BPC-157, TB-500, and GHK-Cu. TB 500/BPC 157 contains only two components. The addition of GHK-Cu in Glow 60 mg introduces a third research compound with its own proposed mechanisms related to extracellular matrix remodeling.
Is 500 mcg of TB 500/BPC 157 a lot?
500 mcg total would deliver 250 mcg of each peptide. For reference, BPC-157 community protocols commonly reference 200–500 mcg per administration, while TB-500 protocols reference 2–5 mg per week. The 10 mg vial contains 5,000 mcg of each peptide, providing multiple doses depending on protocol.
What strength is TB 500/BPC 157?
TB 500/BPC 157 is labeled at 10 mg total peptide content per vial, consisting of 5 mg TB-500 and 5 mg BPC-157. It is supplied as a lyophilized powder in a 2 mL vial.
Is TB 500/BPC 157 lab tested?
Yes. A published laboratory report dated April 26, 2024 measured TB 500/BPC 157 at 5.43 mg TB-500 (108.6% of label claim) and 4.95 mg BPC-157 (99% of label claim). The batch number for this report is #BTHD24.
The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.
How should TB 500/BPC 157 be reconstituted?
Lyophilized TB 500/BPC 157 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.
Related Offers
Domestic & International
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Sermorelin GHRH(1–29) Analog
5 mg/vialStrength 5 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Growth Hormone-Releasing Hormone Analog
Peptide Type GHRH Analog
Manufacturer Dragon Pharma
$27.00
$45.00
Domestic & International
-40% OFF
Dragon Pharma, Europe
Product Information Compound Details
Active Substance Tesamorelin Growth Hormone-Releasing Hormone (GHRH) Analog
5 mg/vialStrength 5 mg/vial
Package 1 × 2 mL Vial
Form Lyophilized Powder
Drug Class Research Peptide
Peptide Type GHRH Analog
Manufacturer Dragon Pharma
$42.00
$70.00